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Sommaire
Une forme pharmaceutique à libération modifiée basée sur un principe
géométrique a été développée et évaluée pour la libération orale contrôlée et soutenue
d’agents bioactifs. Cette forme pharmaceutique est composée d’un noyau biconvexe
obtenu par compression directe, enrobé d’une membrane imperméable à l’exception
d’une surface de libération radiale. La libération de l’agent bioactif se fait à partir d’une
fenêtre radiale de forme cylindrique à un taux relativement constant. Le tartrate de
métoprolol et l’aminophylline ont été utilisés comme modèles d’agents bioactifs. Ces
agents ont été choisis en raison de leurs propriétés physico-chimiques (solubilité). De
nombreuses formulations ont été faîtes pour chaque principe actif avec différents
excipients. Afin de développer un enrobage imperméable pour le noyau et améliorer
l’adhésion entre le noyau biconvexe et cet enrobage, quelques études ont été
effectuées pour évaluer l’efficacité de libération de la drogue, étudier l’effet des
excipients dans la formule sur la cinétique de libération, étudier l’effet de la
concentration ou du niveau de drogue basé sur le rapport de la partie fortement soluble
à la partie moins soluble et étudier l’effet de la surface de libération (non enrobée). Une
étude comparative a été faite pour évaluer l’efficacité de libération de drogue en
employant un noyau plat et un noyau biconvexe (RRBD). L’effet de la vitesse d’agitation
sur le taux de libération a été étudié. L’effet de la force de compression employée pour
fabriquer les comprimés sur le taux de libération a été évalué et la valeur de porosité
sous différentes forces de compression a été déterminée. Toutes les expériences ont
été faites in vitro en utilisant un appareil de dissolution automatisé. Les résultats
I
obtenus à partir de ce projet de recherche ont démontré l’efficacité du dispositif de
RRBD pour contrôler la libération de drogue.
Mots clés: cinétique de libération, noyau biconvexe, membrane imperméable.
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Summary
A drug delivery device based on a geometric design was evaluated for the
controlled and sustained oral delivery of bioactive agents. The device consists of a
directly compressed biconvex core, coated with a totally impermeable coat with the
exception of the radial releasing window. The drug release from these cores radially,
starting from the cylindrical releasing area at the periphery and release the model drug
at nearly constant rate. Metoprolol Tartarate and Aminophylline were used as model
drugs. These model drugs were selected because of their physico-chemical properties
(solubility). Numbers of formulations were made for each pharmaceutical active
principle (Metoprolol Tartarate, Aminophylline) with different excipients. In order to
develop the coating of Radially Releasing Biconvex Device (RRBD) (i.e. to have a
totally impermeable coat) and to improve the interlocking between the biconvex core
and the impermeable coat some studies were made. Several studies evaluated the
efficiency of these devices; study the effect of the level of excipients in the formulation
on drug release, based on the ratio of highly soluble ingredients to low soluble
ingredients, study the effect of drug loading , study the effect cf the releasing surface
(uncoated ), comparative study was made to evaluate the efficiency to control the drug
delivery by usîng flat core and biconvex core coated tablet (RRBD), study the effect of
agitation speed on the release rate, study the effect of compression force used to press
the tablets on the release rate and evaluate the porosity value under different
compression forces. AIl the experiments were made in-vitro by using dissolution
apparatus. The results obtained from this research project demonstrated the efficiency
of RRB device to control the drug delivery.
III
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I. Introduction
A. Overview of modified release drug delivery
During the last decades, research in modified drug delivery has led to
increasingly sophisticated sustain drug deiivery systems. It has also
stimulated greater awareness among the pharmaceutical industry, the
regulatory agencies, the health care profession, and the public at large for
the therapeutic advantages of modified drug delivery systems. Presently,
the majority of these systems are based on the use of synthetic polymers
that differ in their degree of erodibility, swellability, and sensitivity to the
biological environ ment in which they are placed. These polymers have been
used to design systems such as microcapsuies and nanoparticles for
implantation, hydrogels for oral and patenterai drug delivery, the osmotic
pump for oral drug delivery, and patches for transdermai drug delivery. (1)
Drug concentration, aqueous solubility, moleculat size, crystal form,
protein binding, and pK are among the physicochemicai factors that must
be understood in order to design a delivery system that exhibits controlled
or sustained release characteristics. Controlled and sustained release
preparations using alternative routes have been formulated but the oral
route still remains the most widely studied and used. It is obvious that, very
highly water soluble drugs (hydrophilic) are more difficult to deliver orally in
sustained or controlled release manner than hydrophobic drugs. (2, 3)
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J. Generalities
The pharmaceutical dosage form can be defined as a pharmaceutical
system delivering a drug to an organism. There are two different
parameters relating to drug delivery: the amount of drug released over a
unit of time and the drug elimination process, including drug metabohsm
(biotransformation) and excretion. The rates of these two concurrent
processes, physicochemicat and physiological, determine the ength of time
that an effective drug Ieve in the circu’ation to obtain a specific
pharmacological action is maintained. This Iength of time is determined by
the so-called biological haif-life, on which basis duration of drug action can
be established.
A drug characterized by short biological haif-life must be administered
at short intervals to maintain the pharmacological action, which makes
patient compliance difficuit to obtain. The ideal dosage form would be a
once-daily dosage form, i.e., one which when administered once daily
woud remain the therapeutic drug level in the body for 24 h without the risk
of toxic concentration. (4)
2. Considerations
Both of the absorption and elimination processes should be taken in
consideration when considering the theoretical possibilities of prolonging
the time of drug retention in an organism. Therefore the fotiowing
possibilities should be considered:
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Prolongation of absorption
> Prolongation of metabolism
> Prolongation 0f excretion
3. Definitions
Over the years, there has been available a variety of pharmaceutical
dosage forms which have affempted to control the time course and
specificity of drugs in the body; these have been identified by various
names, such as “controlled release,” “sustained release,” “prolonged
release,” and “timed release.”
The term “Controlled release dosage forms” (CRDF) implies that
the drug release kinetïcs, prolonged, sustained, or timed, is predictable and
reproducible from batch to batch and from patient to patient. CRDF is not
influenced by the external environment in which the drug is released, but by
the device itself. The release of active agent is, therefore, largely
independent of external factors.
Sustained release means that the release of the active agent is
constant over time. (5, 6)
Long-acting or prolonged-action system: in which a dosage form
containing a therapeutic substance modified chemically in order to prolong
biological half-life. (4)
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4. Advantages and disadvantages of controlled release
Controlled release delivery systems offer many advantages over
conventional or traditional formulations that deliver the entire active
ingredient over a short period of time. We can summarize them as the
following:
One of the most important advantages that can be achieved by using
sustained release devices is constant blood levels of active ingredient
release requiring considerably less ingredient to produce a given duration of
action in comparison to conventional system.
A second advantage of sustained release system is maintaining the
concentration of a drug between the minimum effective and toxic levels,
(above the minimal therapeutic level), eliminating the peaks and valleys of
the conventional systems.
Controtled release systems usually offer a mean of circumventing the
problems of overdosing and underdosing inherent to conventional
formulations. Controlled release system can be designed in which the rate
of drug release equals to the elimination rate, in order to achieve zero or
near-zero order drug kinetic (steady state). (7)
Controlled release technique makes it possible to deliver the agent
locally by its containment at the site of action. Local delivery and
containment reduces the dosage required and the possibility of side effects.
A good example for local drug delivery system is intrauterine contraceptive
deiivery system, when the stetoids estriol and progesterone are given as
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contraceptive. Theses steroids produce a contraceptive effect at release
rates as low as 10 to lOOpg/day, while the same steroids given systemically
would require more than 1,000 times the local dose to be effective.
Because of the low dose required, a controlled release device can contain
sufficient drug to produce a contraceptive action for a year or more. (7)
To reduce the frequency of dosage during the day, this simplifies the
dosage regimen and reduces the risk of missed doses administered either
by patient or by the hospital staff (to improve patient-comfort), thereby
insuring patient compliance (7)
5. Classification of controlled release dosage forms:
Controlled release dosage forms (CRDF) are designed to maintain
drug plasma concentrations within a therapeutic range. However,
pharmacokinetic response from each CRDF varies from product to product.
The pharmacokinetics information on the drug is an essential element to
determine the feasibility of a controlled-release dosage form for that drug.
Obviously, drugs with relatively short half-lives (less than 6 hours) and
specifically defined minimum therapeutic blood levels would be the most
likely candidates for controlled delivery. Drugs with half-lives in the blood
exceeding 6 h could be dosed in conventional dosage forms such that
therapeutic blood levels would be established and then be self-sustaining,
allowing for twice daily dosing or less. One limitation to this approach would
be encountered with a drug with a narrow safety margin. Furihermore, well
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defined minimum therapeutic blood levels of a dtug generally are difficuit to
establish. (9)
A useful classification of controlled release dosage forms according to
the mechanism controlling the drug release as follows:
a) Chemically-controlled systems
(1) Bioerodible systems
(2) Drug-polymer conjugates
b) Diffusion-controlied systems
(1) Membrane-reservoir systems
ta) Solution-diffusion
(b) Osmotic pumping
(2) Matrix systems
fa) Porous matrix
(i) Geometric-controlled
(ii) Gradient distribution
(b) Polymer erosion
(c) Polymer swelling
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B. Oral con trolled-release drug delïvery systems
1. The design of controlled release systems
Most of the oral controlled release systems rely on dissolution,
diffusion, or a combination of bath mechanisms, ta create slow release of
drug to the gastrointestinal milieu. In order to achieve a systematic
approach to the design of an oral controlled release product, it is necessary
to understand the following:
a) Physicochemical characteristics of the drug
b) Dosage form characteristics and formulation techniques.
c) Gastro-intestinal physiology and pharmacokinetics
A review of the literature has revealed the recent development of
several novel drug delivery systems that can be utilized for the controiled
delivery of drugs in the Cl tract. (1, 10, 11).The following classification of
such systems is chosen because it includes both the conceptual approach
of the design and some elements of physiology of the Cl system.
(I) Continuous-release systems
fa) Dissolution contrai
(b) Diffusion control
(c) Dissolution and diffusion control
(d) Osmoticaily controlled devices
(e) Slow-dissolving saits and complexes
(2) Delayed-transit and continuous-release systems
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ta) Density-based systems
(b) Size-based systems
(c) Bioadhesive-based systems
(3) Delayed-release systems
(a) Intestinal release
(b) Colonic release
2. Dissolution control
When a tablet or other solid dosage form is introduced into a beaker of
water or into the gastrointestinal tract, the drug begins to pass into solution
from the intact solid form. Unless the tablet is a contiguous polymeric
device, the solid matrix also disintegrates into fine particles and/or granules.
Disintegration, deaggregation, and dissolution may occur simultaneously
with the release and dissolution of drug from its delivery form.
Drug release over a prolonged period can be achieved by employing
dissolution as the rate-limiting step in drug release. The delivery of some
drugs is inherently sustained because of their intrinsic low aqueous
solubility which. Examples of drugs in this category include Griseofulvin,
Salicylamide, and Digoxin.
While for highly soluble drugs, the solubility rate can be controlled by
one or both of the following:
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a) Coating of a drug particles or granules with materials of varying thickness
having low solubility
b) Dispersing the drug particles into an insoluble polymeric matrix
The main principle of dissolution control is as follows: (12) when the
dissolution process is diffusion layer controlled, where diffusion from the
solid surface through the aqueous diffusion layer (stagnant liquid film) to the
bulk solution is rate limiting, the flux J is given by:
J=—D(dc/dx) (Equation 1)
Where,
D = the diffusion coefficient
dc/dx = concentration gradient from solid surface to the bulk solution
The flux can also be defined as the flow rate of material (dm/dt)
through a unit area (A):
dm/dt
(Equation 2)
If the diffusion layer thickness is h and the concentration gradient is
linear,
(dc/dx) = (,
— C )/hS (Equation 3)
Where,
Cb = concentration in the bulk solution
9
C = concentration at the solid surface (saturation)
By combining the above equations, the flow rate of material is given
by:
(dm/dt) = (DA/h)kC
— Cb ) = kA(Ç — Cb) Eq. 4
Where,
K = the intrinsic dissolution rate constant.
Equation 4 predicts constant dissolution rate if the thickness of
diffusion layer, diffusion coefficient, concentration difference, and surface
area maintained constant. However, as dissolution proceeds, the surface
area decreases.
A practical expression that describes the dissolution of dosage forms
of various geometries is available (13)
Thus,
M /M = 1 — [(1
— k t)/c a]”t ° ° (Equation 5)
Where,
= the amount of drug released in time t
Mc= the amount of drug released at infinite time
a = the thickness
n = to 3 for a sphere, 2 for a cylinder, 1 for a slab (1)
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3. Diffusional systems
In diffusional systems drugs can diffuse through polymeric matrix
while either leaving the latter intact or the polymers themselves may
undergo subsequent biodegradations following exhaustion of the drug.
Biodegradable systems do flot need to be surgically removed after therapy.
The simplest example of a diffusional system is one in which a drug is
included in a reservoir (core) from which it can diffuse out through a
membrane. The kinetic behavior of a drug can follow zero-order as long as
the drug concentration in the core is maintained in highly saturated state.
4. Reservoir devices
Reservoir systems are commonly used in the field of controlled
release, as diffusion-controlled systems. To achieve optimum therapeutic
effects particularly for drugs with short biological half-lives, it is often
desirable to have a zero-order drug release. The kinetics of drug release
from such a membrane-reservoir system generally follows either a
solution-diffusion or an osmotic pumping mechanism. In a membrane
reservoir system, a water-insoluble polymeric material encases a core of
drug. Drug will diffuse through the membrane and exchange with the
media surrounding the tablet or particle. Additional drug wilI enter the
membrane, diffuse to the periphery, and exchange with the surrounding
media. b keep the drug release constant, the reservoir must be
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saturated. The movement of drug or solvent is governed by membrane.
The membrane permeability to the solvent and the drug determines the
diffusion rate of molecules through the membrane. The most important
advantage of using reservoir systems is the possibllity of achieving a
constant rate of release over a substantial portion of their lifeUme. A
second advantage is that the level of drug loading can be higher
compared to other systems.
Figure 1: Reservoir device
The diffusion rate across the membrane is given by Fick’s law:
J = —Ddc/dx (Equation 6)
A c e ni
Membrane
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Where,
D = diffusion coefficient in area / time
dcldx = the change of concentration C with distance x
At steady state, equation (6) is integrated to give by
J—DAC/1? (Equation 7)
In terms of the amount cf drug released, the release rate dM/dt is
given by
dM / dtzzADKAC / £ (Equation 8)
Thus,
A = the area
D = the diffusion coeffïcient
K = partition coefficient cf drug between the membrane and drug core
f = the diffusional path length (thickness of coat in the ideal case)
1X0 = the concentration gradient across the membrane
A significant factor in Equation (8) the partition coefficient which is
defined as the concentration of drug in the membrane over the
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concentration of drug in the core. If the partition coefficient is high, the
core wîII be depleted of drug in a short time so that zero order release will
be observed only over a short segment of the time course of drug release.
In fact, to get a constant drug release rate from a reservoir device it is
crucial to keep constant area, diffusional path length, concentration, and
diffusion coefficient. (1,6,7, 15)
5. Effect of device geometry on drug release rate
As discussed previously the diffusional controlled matrix systems have
some advantages over other systems particularly when compared to the
fabrication of reservoir systems. A main disadvantage is that they do flot
inherently possess zero-order release kinetics. However, these systems
can avoid the diminishing release rate as the drug diffuses from longer
diffusion Iength or lower drug concentration distribution. This difficulty is
particularly severe for spherical and cylindrical shaped devices. An
achievable sotution to get zero-order release behavior is to modify the
matrix geometry. Examples of different geometries, e.g. pie, hemisphere, or
cone are illustrated later.
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Fïgure 2: Comparison of different geometries (slab, cylinder and sphere
geometries of reservoir systems
The rate of release of an active material from a reservoir device can
be controlled through geometric factors. Equation 6 can be modified for the
slab or sandwich geometry as show in Figure 2
dM /dt=AJ. /Ï=ADKC Il
t lilTi S
Where,
(Equation 9)
M is the released drug mass at time t and since dM/dt is the steady
state release rate at time t. A is the total surface area (edge effects being
ignored), and Jiim is the membrane-limiting flux. (7)
For the cylinder, the steady-state release rate (ignoring end effects) is
given by
fa)
SIab
(b)
Cy1nder
eaero
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cliv! / dt = 27rhJ1. / 1nr0 /i = 2,rhDKC / ln(r0 / r) (Equation 10)
Where
r0 and r1 are the outside and inside radii of the cylinder, respecfively,
and h is the iength of the cylinder.
For the sphere,
r r. 4îcDKC r r.
dM/dt=4irJ. 0 i =SO± (Equafionil)
llffir
—r r —rOi Oi
The sphere is a particularly interesting geometry since in the limit as
r0/r — cq dMt/dt—>47cDKC1
That is, the release rate becomes independent of the outer radius of
the device, r0. A plot of flux against the ratio r0/r1, as illustrated in Figure 3,
when r0/r exceeds approximately 4, further increases in device size for a
fixed radius core does not significantly affect on the release rate. Since
almost ail the concentration decrease is within a distance of a few radii of
the inner core. Thus, a given size reservoir provides a constant release rate
for any thickness of membrane beyond a certain limit, making membrane
thickness a noncritical parameter in device fabrication.
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Figure 3: Release rate against membrane thickness for different
geometries of reservoir devices
Increasing membrane thickness with the various other geometries
affects release rate quite differently. As shown in Figure 3, in which the
release rate is plofted as a function of membrane thickness for devices of
various configurations. In figure 3 it is obvious that none of these
geometries give zero-order release for the following reasons. For the slab
geometric device, the area remains constant, yet the distance of the
receding boundary from the releasing surface increases with Urne.
Therefore, the increase in diffusional path length results in a release rate
25
1.5
1-o
0.5
o
8 12 1 20
Aembtan Thcknes or Ç)
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17
that decreases with time. The release rate is inversely proportional to
thickness, and release rates are thus easily scaled over a wide range. For
the cyflnder and the sphere, the decrease in the release rate ïs more
pronounced, since the area decreases with time, whereas the distance of
receding boundary increases with time.
a) Matrïx device systems
Diffusional matrix systems are the earliest most utilized means of
bioactive agents delivery. In this system the drug particles are dispersed
uniformly in an insoluble polymer. The drug releasing rate is governed by
the penetration rate of surrounded medium into the matrix from the
surface. This, in turn, is controlled by the porosity of the tablet matrix, the
presence of hydrophobic additives, and the wettability of the tablet and
particle surface.
When s diffusional rnatrix system cornes in contact with an external
medium, as the drug dissolves, the diffusional path length increases
because as the dissolution front recedes from the surface.
The main disadvantage of matrix devices is that drug release rate
continuously decreases with time. This is an end result of increased
diffusional distance and decreased surface area at the penetrating solvent
front; therefore it is not possible to obtain zero-order kinetic by using this
kind of device. The geometry can be modified to compensate for the
increase in diffusional distance through a corresponding increase in
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surface area for dissolution, thereby increasing the amount cf solubilized
particles per unit of time resulting in near zero order release from matrix
device. (16, 17)
In this matrix system the releasing rate of a drug is based on the
diffusion rate of a drug. Higuchi’s equation can be used to express the
amount cf drug released from this device:
Q = [Ds/T(2A—&c 7 (Equation 12)
Where
Q = drug released in g per unit surface area
D = diffusion coefficient of drug
E = porosity of the matrix
n = turtousity of the matrix
C = solubility of drug in release medium g/ml
A = concentration cf drug in the tablet
b derive this equation the following assumptions were made:
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‘- The particles size of the drug is much smaller than particles in the
matrix
> No interaction between the drug particles and the matrix
> Constant diffusion coefficient
A pseudo- steady state is maintained during release
C = O in the bulk solution at ail times
A » Cs f saturated conditions)
This equation can be reduced to
1/2QzKt (Equation 13)
A plot of drug reieased (mg) versus the square root of time should be
linear if the rate drug release is diffusion controiied. The rate of drug
release from a homogenous matrix can be controlled by changing one of
the following parameters :( 18)
• The soiubility of drug
• initial concentration of drug in the matrix
• Porosity of the matrix
• Tortuosity
• Leaching solvent composition
• Polymer system making up matrix
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Membrane-coated tablets were developed to provide a dosage form
which exhibits zero-order kinetics. The delivery system consisted cf a
soluble tablet core surrounded by a porous membrane which controls the
diffusion rate. The water from the gastric juices diffuses through the pores
to reach the core to dissolve the drug which then diffuse back through the
water filled pores and eventual release into the gastric juices. Such a
device using membrane coating as a diffusional barrier is represented in
Figure 4 Membrane-Coated Tablets (19):
Figure 4: segment of membrane-coated tablet (A) lïquid penetrating into the
membrane, and (B) drug solution diffusing through the membrane.
The rate of release cf drug from the tablet through the pores can be
calculated by using Fick’s first law cf diffusion.
A B
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Q = DC5,
—
C J A/h (Equation 14)
Where
Q = rate 0f release
D = diffusion constant
A = surface area
h = thickness of the diffusion layer (i.e. film)
As long as there is a saturated solution together with solid drug
substance inside the coating shell, the concentration inside the coating
sheli, C, is much higher than the concentration outside the coating shell,
C. which means C is negligible compared to C and equation (14) can be
reduced to:
QDC /hA (Equation 15)
This implies that the diffusion should proceed at a constant rate (zero
order reaction). At the point where no solid substance is left within the
membrane coating, the rate of diffusion declines with decreasing
concentration (first-order reaction).
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C. The influence of geometric design
1. Dissolution of solid dosage forms
Once a solid dosage form is placed in a Iiquid medium dissolution
begins. The dissolution rate cf a solid dosage form decreases with time
because of the decrease in dissolution front surface area. Furthermore, the
diffusional path length increases making it difficult to keep the release rate
of drug in constant level and then no zero-order kinetic. From that point the
geometric design promises to overcome the decrease in dissolution front
surface area.
The familiar cube-root law for dissolution of solids was derived by
Hixon and Croweil on the basis of diffusion away from the surface of a
spherically-shaped solid. The convex surface of a sphere decreases in area
as solid mass is lost from the surface so that the dissolution rate decreases
in portion to the decrease in area until the solid is completely dissolved. By
including shape factors, this model has been extended to describe the
dissolution of varlous prismatic forms (20). As in the case of spherical
particles, the dissolution rate decreases with time as the dissolution process
progresses because of the decrease in area.
The surface area in the case of a concave device increases as solid
mass is eroded from the surface. Therefore the rate cf dissolution increases
with time. Rippie and Johnson (21) studied the dissolution characteristics of
solid pellets that were designed to minimize loss in surface area during
dissolution. This was accomplished by employing pellets having a cross
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section such that both convex and concave surfaces were present.
Dissolution rates of pellet cylinders having a cross shape and clover leaf
cross sections were measured and compared with that of a right cîrcular
cylinder. Although the dissolution rates of the uniquely-shaped pellets
decreased over time, with partially coated pellets the rates decreased much
less than that of the circular cylinder, e.g., after 60% mass loss the rates
were approximately 55% greater than that of the circular cylinder.
When a hole is present in a nondisintegrating tablet, the convex
surface of the hole will increase in area as the surface dissolves. A
theoretical analysis by Cleave (22) on tablets in the form of parallelepipeds
indicated that the presence of one or more holes in a tablet can alter
significantly the dissolution rate of the tablet over time. It was concluded
that a two-hole tablet is basically a better configuration than the others for
maintaining a constant dissolution rate. (14)
2. Geometrically Modified Systems
The diffusion-controlled monolithic matrix systems have some
advantages over other systems especially when compared to the
fabrication of reservoir systems. A major disadvantage is that they do not
inherently follow zero-order release kinetics. However, these systems can
overcome the decreasing release rate as the drug diffuses from longer
diffusion length or lower drug concentration distribution. This difficulty is
particularly severe for spherical and cylindrical shaped devices. Geometric
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factors have been utilized to compensate for the increasing diffusional
distance and decreasing area at the dissolution front generally encountered
in matrix systems. Many geometrïc designs have been proposed in the
literature which modifies the planar geometry of a matrix device from which
the fraction of drug released was linear with the square root of time (23, 24).
3. Planar geometry
The release kinetic of a drug from planar geometry composed of a
homogenous matrix, where the amount of drug released from planar device
into the surrounded media acting basically as a perfect sink can be
described by the following retationship;
QDt[2A_C C (Equation 16)
Where,
Q = drug released after time t
D = drug diffusitivity
A = the total amount of drug present in the matrix per unit volume
C= drug solubility in the matrix substance.
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For the release from a planar system having a granular matrix
composed of dispersed drug particles in an inert polymer. The above
relation must be modified to account for the effective volume where
diffusion can occur and the effective diffusionat path. It can readily be seen
for this system that
QD&/T[2A—c Ct (Equation 17)
Where,
Q = the amount of drug released after time t per unit exposed area
D = the diffusivity of the drug in the permeating fluid
r = the tortuosity factor of the capillary system 3
A = the total amount of drug present in the matrix per unit volume
C= the solubility of the drug in the permeating fluid
E = the porosity cf the matrix
The origin ofthe above expression is basically the same as for Eq.16,
except that the effective diffusional cross sectional area must be reduced by
the porosity factor E, and the solubility of the drug in the total system per
unit volume must also be decreased by the same factor.
The tortuosity factor, T, is introduced to correct, for the tengthened
diffusional path caused by the necessary lateral excursions.
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For both equations (25) it is assumed that there exists a pseudo
steady state condition during the release process and that the drug pattîcles
are quite small and is uniformly distributed in the matrix. The equations
would be fundamentally valid for systems in which A is greater than C or
EC by a factor of three or fout. 0f course, if A < C or ECs, the dtug would
flot longer be ptesent as a solid and a different equation would be apply.
Since the potosity factor in Equationl7 refers to the porosity of the
leached portion of the pellet, it diffets from the initial porosity of the initially
formed matrix. The difference would correspond dîrectly to the volume of
space previously occupied by the exttacted component or components.
Thus
+KA (Equation 18)
For systems where the drug is the only extractable component, K
being introduced to convert A to its corresponding volume fraction. K is
equal to the specific volume of drug = II (density of the drug) if A is
expressed in terms of grams of drug per milliliter. For those instances
where the initial porosity, E0, is very small or where the fraction of the matrix
volume occupied by the drug is relatively large E KA and equation 17
reduces to
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QAJDK/T[2KC Ct (Equation 19)
Therefore in this system the amount of drug released at anytime is
basically independent of A.
4. Multi-layers tablet and cylindrical geometry
To design controlled release dosage forms for oral use there are
various ways: from tablets or capsules, film coated pellets, to more
complicated drug delivery systems. Hydrophilic matrix systems are
considered to be the easiest way to formulate a drug into a prolonged
release dosage form. Generally the mechanism of drug release from
hydrophilic, swellable matrices couples polymer macromolecular relaxation
with drug diffusion with the resulting kinetics depending on the relative ratio
of relaxation to diffusion. (26, 27)
Cone et al. (28) developed a multî-layer tablet system (Geomatrix®) as
shown in figure 5
2$
Figure 5: Schematic diagram of triple-layer tablets (Geomatrix©)
A core tablet is sandwiched between two barrier layers. By using
hydrophilic swellable/erodible polymer zero-order kinetics can be achieved.
However, zero-order release kinetics also depends on the solubility of
drugs. 1f the two layers were hydrophilic swellable polymec, the drug release
rate is controlled by several mechanisms. When the device is placed in
water, hydration of the polymer will start and then the drug diffuses toward
the surrounded media. When liquid penetrates through the barrier layer, the
drug will dissolve and then diffuses out. Then the swollen barrier can be
considered as a membrane. lnitially, the drug kinetic release is governed by
the diffusion of drug through the swollen barriers because the total lateral
surface area is greater than the radial surface area. Core tablet hydration is
delayed due to the drug-fcee barrier layers. In addition, the thickness of the
swollen barrier layers diminishes with time, leading to a decrease in the
diffusion resistance of the membrane. This counterbalances the effect of
the reduced concentration of the drug in the core tablet on the drug release
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kinetics, leading to the prolonged zero-order release. Sînce, the release of a
drug from this system is essentiaily based on the solubility of a drug, when
the solubility of a drug is low, then the release kinetic can be much close to
zero-o rder.
Formulating tablets containing different dose levels with identical
release kinetics is considered to be the greater source of trouble during the
development of controlled release dosage forms based on tablet geometry
The tablet design necessitates altering the formulation and tablet size.
Therefore, each tablet requires a unique formulation for each dose level.
Cone et al. (29) developed small tablets with multi-layer system design
which can be placed in a hard gelatin capsule. In this system, the release
kinetics of different dose levels shows the same release profile.
This multi-layered tablet system has been reserved to press-coated
tablet system. The press coated tablet system consists of an outer low drug
(or drug-free) content layer and a high drug content core (30). This device
was prepared as follows: A specific amount of blend of coat excipients is
put into a die (bottom layer) then compressed with a flat-faced punch
followed by placing the core tablet in the middle of the bottom layer. The
rest of the mixture is then poured into the die forming the side and top layer.
In press-coated system the drug release delay by the coating barrier varies
according to the coat thickness and the type of materials. The barrier is able
to slow down the hydration/swelling process of the core tablet for a long
period of time. Further more, the outer barrier layer works as a controlting
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membrane producing a linear release profile as long as the drug
concentration in the cote is at saturation level.
5. Spherical geometry
By applying the Fick’s first Iaw in this system
Qt=—4zcr2DdC/dr (Equation 20)
Where,
Qt = the diffusion rate
D = the diffusion coefficient of drug molecu les in the matrix
o = the concentration of the drug in the polymer
As in the cylindrical geometry approach and under the same boundary
conditions and presuming that the diffusion rate of solute from the matrix is
constant (pseudo-steady state), the next equation can be derived:
Qt = 4D (CM —CbK) (Equation 21)
[ï / RQ)}—[1/R0]
Similar to the cylindrical geometry, as equation 21 shows, the
concentration profiles for the pseudo-steady assumption are no longer
linear with respect to the radius. The following equation is achieved, which
illustrate the correlation between R (t) and t.
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CT R2
(Equation 22)
D(CM
It is obviously that ail of the three different geometries do not follow
zero-order kinetic release behavior for different reasons. In both cases of
sphere and cylinder the decline in the release rate is more marked,
resulting from the decreasing in the area with time, and the increasing
diffusional distance because of the receding boundary. In the case of slab
geometry the main cause is that while the surface area stays constant, the
diffusional distance increases with time.
D. Controlling release rate with geometric matrix systems
a) Pie shaped system
Brook and Washkuhn (31) have presented the pie shaped device to
deliver a drug in order to reach zero-order kinetic. The release of a dtug
from a polymer matrix could be governed by dissolution or diffusion. The
principle of this design is based on compensating for the increase in
diffusional path length by increasing the dissolution front area thereby
increasing the amount dissolved within the device. The device composed
of a nonpermeabie section of a cylinder with a cavity having a circular
sector cross section as shown in figure 6. The cavity communicates
(releasing window) with the medium (fluid) in which the device is placed
3R0 2
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nonly through a narrow opening of width a. The release from this device
was tested by following the release of stearic acid into ethanol. The device
has demonstrated a good linearity following an initially higher rate, “burst”
The ideal behavior of this device depends in theory, however, on both the
drug molecules and the releasing window through which they must pass
having infinitely small dimensions.
Figure 6: Cross section of zero-order drug delivery system containing solid
drug
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Lipper and Higuchi (32) took the size of the opening into their
considerations to present a theoretical expression for drug release from
pie-shaped devices. The flux J, for diffusion path length s, is given by:
J = 2OirLD(s+n ‘c (Equation 23)
ds
Thus,
J = the flux at r
O = the half-angle of the pie
D = the diffusion coefficient of the drug in the dissolution medium
S = the diffusion path length
n = the opening radius
C = the drug concentration
At pseudo-steady state (constant flux), integration of equation (23) with
respect to both distance and concentration yields:
2OLD(C -C)
J = S (Equation 24)
‘n—
I’Z
Where
C = the drug concentration at the drug dissolution moving front
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Cb the drug concentration at the opening
À = the distance between the centre cf pie device and the moving front
However, diffusion from the opening cf the device into the surrounded
medium is expressed for sink conditions by:
J2OLDnCb /h (Equation 25)
Where
h = the stagnant film thickness
By solving equations (24) and (25) for Cb, and taking into account
the mass dissolved at time t, M = (Â2 — n2) LOp, the following relationship
between the mass dissolved and time can be obtained:
[M+1/Lepn2l
T=[h/n —1/2)1v! +LOp 2/2] In
2OLDC
ffquafion 26)
However, if one considers the mass dissolved in the diffusion layer
between Â and O, the following equation may be derived for relating À and
Mr:
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lir
— n2 LOp — LOC8 + LOCH — LOC 1n (Equation 27)
2—+1n —+ln—
n n n n
Hanssen et al (33) and Conte et al. (34) developed the perforated,
coated tablet (PTC) and Boeffner et al. (35) presented the multi-perforated
trilaminate. A single perforated tablet, (as show in figure 7), is made by
direct compression of drug and other excipients (magnesium stearate and
lactose). Then the device was coated by spraying a polymer solution and
after that a central hole has drilled.
Figure 7: Cross-sectional view of a coated I perforated device
In this device the relationship between the drug release kinetics and
the size of the hole is directly proportional; because of the increasing in
inner releasing surface area as the dissolution front moves the kinetic
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release of the drug from this device is linear. However, Hanssen et aI. (36)
when a water insoluble polymer ïs integrated into the matrix a
considerable decrease in the rate of dissolution followed with obvious
deviation from zero-order manner was observed.
Conte et aI (34) made-up perforated coated tablet with a central
hole by spraying a coating solution. This device is consisting of
hydrophobic polymer; the central hole represents the window through
which the drug is released to the surrounded medium, as long as the
diffusional length increases the surface area at the dissolution front
increases, giving a good linearity. During the coating operation, however,
the inner surface of the central hole may be coated to form a film
ng
Figure 8: Cross section of a perforated coated tablet
Dru
E.c ipients
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Equation (27) can be modified ta calculate the amount of drug
released from perforated-coated tablets by replacing 8 with n as:
M ‘22’[L7rp-L7rC+L7rCJr 2(Ji/n+1n/n) ] h/n+lnÂ/n
b) The multi-perforated device
(Equation 28)
It is composed of two layers coating the top and bottom side of core
matrix. In this device the coating layers are totally impermeable ta the
drug. Circular perforations are punched from the top ta the bottom. On the
other hand, the drug can only release through the perforated hales and
uncoated sides. The amount cf drug released from this device basically
depends on the number of perforations and size of the device as weII.
(37). Model equations have been developed to predict the release of drug
from the mufti-perforations as follows for a coated edge:
Mr = — n2)LICE p — C5 +
—n2)pv +2rp1n
2 n
2DC5
Equation 29
Equation 30
ivr n
— 1z6
nr n
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And for an un-coated edge,
M,. = N(2 — )Ls[P
—
+ 2+1n][± ]+s[—EC)Ct]’
Equafion 31
Where
and t are the porosity and tortuosity of the matrix, respectively, N îs
the number of holes, and S is the surface perimeter of the edges.
uncoatcd edges coated edges
Figure 9: Schematic diagram of morantel sustained release trilaminate
Kim (38) proposed a simple un-coated-compressed (swellable
/erodible) tablet with a central hole (donut-shaped). In this device the
kinetic release is zero-order (i.e., 80
— 90% of theophylline was released)
before rapidly decreasing. The release of drug in this system depends on
the size of hole when the hole size is increased from 5/32” to 7/16”, the
J
o o o
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/
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release rate încreases and it is obviously that the time needed for release
ïs shortened.
The combined process of boundary erosion and diffusion front
progression during drug release from the donut-shaped tablets, Figure
10), compensate for the decrease of releasing surface area from the outer
surface by the increase of releasing surface area from the central hole. At
the end of drug release, the swollen gel thickness of the donut-shaped
tablet is thin enough to be broken by fast stirring. (39)
Figure 10: Schematic diagram of releasing surface area boundaries
However, if the hole size is smaller than 5/32”, the hole collapses
during drug release due to the inner swelling of the polymer from the
central hole. As a result, the drug release from a small hole donut-shaped
tablet tends to follow the drug release from the tablet without a hole.
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Kim (40) has developed coated donut-shaped tablets, an
improvement of perforated-coated and donut-shaped tablet. Water-soluble
polymers and swellable/erodible polymers have been used in perforated
coated tablets. In this system, drug diffusion and/or polymer erosion
govern drug release kinetics, providîng parabolic or linear release profiles.
c) Cone-shaped and Hemisphere Systems
Nelson et al introduced the cone-shaped device, Figure 11, this
system is essentiatly based on the theory that the surface area at the
diffusional front increases as the diffusional path increases. The device
consists of a non-permeable coat at the two sides (top and boffom), and
then the drug can be in between or dispersed in the matrix. The drug can
be released through the small hole at the bottom of the cone. Once the
Iiquid starts to penetrate through the hole, a drug-depleted layer forms
between the opening of the hole (a) and the solid suspension interface (r).
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Figure 1f: Cross-sectional view of a cone-shaped device
Nelson et aI. (41) treated the release of drug from the device as a
pseudo-steady state diffusion in a hallow sphere with a declination angle
8.
Hsieh et al. (42) studied the release kinetics from a hemispheric
matrix as presented in Figure 12 in which the device is coated on ail
surfaces with an impermeable coating except for an orifice in the centre
face. Hemispheric systems for Iow molecular weights drugs were prepared
by heating and compressing poly-ethylene and drug (sodium salicylate) in
a brass mold. Hemispheric systems for high molecular drugs were
prepared by casting ethylene-vinyl acetate copolymer and protein in a
hemispheric mold at
— 80° C, followed by a two-step drying procedure (-20
and 20°).
a
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coared
Experimental analysis of the device demonstrated that a
hemispherical, receding layer is produced, with the radius of that layer
increasing as a function cf time. Theoretical analysis was also
accomplished to develop release equations for the hemispheric device. In
the theoretical analysis, it was supposed that the amount of drug present
per unit volume, C0, is substantially greater than the solubility of drug per
unît volume of the vehicle, Os. It is also assumed (43), which the solid
drug dissolves from the surface layer of the device first. When the layer is
depleted of drug, the next layer begins to be depleted. The interface
between the region containing dissolved drug and dispersed drug moves
into the interior as a front. According to these assumptions, and several
others, the release rate equation was derived as follows:
Fïgure 12: Hemisphere design
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dQ
= 2C DA t) (32Equation 32)
dt S t
Where
C = solute solubility in the polymer
D = diffusion coefficient
R (t) = radius of the receding boundary
A1 = radius of the spherical cavity
When R(t)» a, equation (32) is reduced to
d%/2ICCDA (33Equation 33)
Equation 33 shows that the release rate is independent of time, t, and
therefore a zero-order release kinetics is atlained.
U) Biconcave disc
Benkorah and McMullen (57) have presented a biconcave disc. It is
composed of a slow-dissolving biconcave core of a drug /excipient mixture
coated with a totally impermeable membrane. After coating an opening is
made through the center of the disk to expose a cylindrical releasing
sur[ace which represents the only way by which the device can contact
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the surrounded medium. In this device the release kinetics depends on the
increase in surface area at the dissolution front to counterbalance the
Iengthening of the diffusion path.
d.
Figure 13: three dimensional cross-sectional view of the biconcave device
fa) Dissolving cote, (b) impermeable coating, (c) teleasing hole, f d) tablet
angle, (A) hole radius, (H) hole height.
Studies cf the effect of the geometry of the proposed device
suggested that release rates, can be predetermined by controlling the
diameter of the hole provided that suitable formulations are selected. The
study also proposed that constant release rates are better achieved with
smaller holes. A high altering from zero-order is obvious as a result cf
J,
b”
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large hole size large, mostly when formulations of highly soluble drugs,
with high intrinsic dissolution rates, were used.
Another approach, developed by Bechard and McMulIen (45)
illustrates kinetics profile 0f a drug from a polymer matrix device. This
device is composing of polymer matrix with a central hole, inwardly
tapered disk which was planned to be implanted in order to release
bioactive materials at a constant rate over an extended period of time.
Figure 14: Cross sectional vïew ofthe proposed device (S. Bechard and
McMullen; solute release from a porous polymeric matrix)
The principle of this approach based on the increases in drug
diffusion path followed by the increase in area of the dissolution boundary.
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In this approach a biconcave polyethylene disc matrices with a releasing
hole on the center. (44, 45)In this research there were two types of matrix
fabricated by compressing a sodium salicylate-meit polyethylene blend
with sets of conical punches having two different angles (20° and 30°), with
an axis perpendicular to the cone. The matrices were covered with wax
and a hole in the centre was made to generate area through which the
solute releases could occur. An approximate mathematical solution was
developed for these devices and tested against experimental resuits. The
solute release from this device is given by:
P(2R3+ 3AR2)C{2R3++ 1n4AR+2}
L —
1hus
6AD’Cs
(Equation 35)
Mr = the mass of solute released
t =thetime
O = the angle between the surface of the device and a horizontal plane
Mr
3
And
fEquation 34)
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Passing though the mid-height of the disk
D’ the diffusion coefficient of solute in the dissolution fluid divided by
The tortuosity (r)
E = the porosity cf the matrix
C = the solute solubility in the dissolution fluid
R = the distance from the dissolution front to the centre of the hole
A = the radius of the releasing hole
The experimental resuits and theoretical model using this matrix
device demonstrated that this matrix geometry design could be valuable
as a pharmaceutical dosage form to control the release of solute
according to zero-order kinetics.
E. Powder characterïzation
1. Density
Density is the weight to volume ratio of a substance, expressed in
g/cm3 or lb/ft3. Powders that the pharmacist deals with can be characterized
by dïfferent types of densities which can give useful information about a
powder and its constituent particles. And since powders normally flow under
the influence cf gravity, dense particles are generally less cohesive than
less dense particles of the same size and shape. If a powder is poured
(cascaded) into a container, it forms a bed, part of which is solid, part of
which is void space (air). (46, 47)
In work with solids there is the following conventional density terminology:
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• True or absolute density (p) is the weight to volume ratio of only the solid
portion of the powder particles, i.e., the mass of 1 cm3 of nonporous
crystal.
• Bulk density or the ratio of the weight of a powder to the volume it
occupies expressed in the same terms as the true density. This density
term accounts flot only for the volume of the solid portion of the particles
(true density), and the voids within each particle (internai porosity), but
also for the voids between the particles.
• Tap density: This is the density of a powder when the volume receptacle is
tapped or vibrated under specified conditions while being loaded. Each
particle of a solid material has the same true densïty after grindîng, milling
or processing, but more geometric space is occupied by the material.
2. Moisture content
The problem of hygroscopicity is of importance in pharmaceutics. If a
drug product is to be made, and if it is known that it is moisture-sensitive,
then obviously it cannot be allowed to pick up large amount cf water during
processing. The use of air conditioners is widespread, but capacities of
such systems vary. (48, 49)The important aspect is to know how much
moisture a solid substance will pick up at given conditions and to then
assess how to change the surroundings so as to keep the quality of the
drug product intact or optimum.
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The moisture content of a wet solid is expressed as kg 0f moisture
associated with one kg of the moisture-free or “bone-dry” solid. A moisture
content of 0.4 kg of removable water is present per kg 0f the dry solid which
will remains after complete drying. It sometimes expressed as % moisture
content.
3. Powder flow properties
Powders are generally considered to be composed of solid particles of
the same or different chemical compositions having equivalent diameters
less than l000pm. However, the term ‘powder’ wiII also be used here to
describe groups of particles formed into granules which may have overall
dimensions greaterthan l000pm.
There are two main factors that affect powder flow: particle size and
particle shape. The doser a particle is to spherical the better it flows (50).
SmaIl particles are very cohesive, making the flow poor (51) and (as a
whole) increasing the particle size will improve flow.
If a powder flows poorly, then some improvement can at times
attained by means of a so-called glidant. Talc is an example of a glidant.
Often, however, this is not sufficient in itself to improve the flow sufficiently,
and other means of flow improvement are necessary. (52)
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Carr has been able to demonstrate that the percentage
compressibility, C, of a powder bed gives an indïcation of the flow
characteristics of the powder:
C
= (flf Po /f3f) X100
Where Po is the initial bulk density and fis the constant density.
4. Partïcle size analysis
Particle size analysis is the mean by which changes in size dîstribution
of powder particles is determined as a resuit of miHing, and for purpose 0f
tablet making, can be divided into two ranges:
1. Subsieve size range-1 OOpm or smaller
2. Sieve size range-44pm or larger
Although there is an area of overlap, each particle size range requires
different methods of analysis, but both ranges use essentially the same
mathematical treatment for the characterizing of the size distribution.
There are many methods of analyzing particle size distribution and
mean particle size.
1. Sieve analysis.
2. Stream scanning.
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3. Sedimentation in Gas or Liquid.
4. Optical Microscope.
5. Laser diffraction.
6. Laser diffraction.
SieveAnalysis
This is the most widely used method of determining the size distribution of
a powdered and granular material. Sieves are generally used for grading
coarser particles; if extreme care is used, however, they may be employed for
screening material as fine as 44 micrometers (No. 325 sieve). Sieve analysis
15 a good method to cover a particle size from 44pm and greater. (53) The
data collected from the difference in the tare weight of each screen and the
total weight of the tare and the powder is entered in table form, and the
cumulative percentages calculated. The mean of the class interval is obtained
by taking the average of each pair of adjacent screens in the nest, e.g., 12
mesh= 1680pm and 20 mesh= 840pm: the mean of the class interval would
be calculated to be:
(1680+840)/2 =1 260pm
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F. The objective of this study
The most important objective of this study is to evaluate the effect of s
geometric design of a coated core for an orally controlled drug delivery
device, and to optimize the formulation of the cote by manipulating the
drug/excipients ratio, drug loading and hydrophilic additive level
(magnesium stearate), in order to get as close as possible to zero-order
kinetics release behavior. The proposed device involves a particular
geometry that is expected to counterbalance the increase in diffusional path
by increasing the area of the dissolution front with time.
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II. Materials and methods
A. Materials
1. Chemicals
Metoprolol Tartrate, USP, (Sun, lot no. 109585) used as a model drug
Aminophylline (Anhydrous), USP, lot no. D65854110 used as a model
U rug
> Lactose (spray dried ), USP (Anachemia Ltd, Montreal, lot No. 481005)
was used as diluent
)- Ethyl cellulose, N.F. (The DOW chemical, lot. No. 840801-6) was used as
impermeable compressed coat.
Magnesium stearate, MS, Fisher scientific, jersey city, NJ., lot 765987)
Chitosan, Practical grade (Sigma, St. Louis) lot No. 92H77031
> Methyl cellulose, USP, 4000 Centipoise (Medisca), lot no. MKJ2OI2NO1
..- Sodium chloride, potassium chloride, potassium phosphate monobasic,
sodium phosphate dibasic, sodium hydroxide and hydrochloric acid were
of reagent grade and used as received for buffer preparation
- Eudragit RS P0, powder(Rohm Gmbh), lot No. 0450938222
2. Instruments
> Turbula mixer (Wab Switzerland)
> Carver Laboratory press ( model C,F. Carver lnc.,NJ)
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Hewlett Packard spectrophotometer (Model HP 8452 diode array)
Dissolution apparatus (Distek, Model 2100,NJ) with the USP XXII paddle
method
Diffusion celI
Tempered steel die withl cm diameter, flat punches, and biconcave
punches having 200 angle with a central hole
> Pharma test PTG-1 used as a flow meter
> Auto tap
Sartorius MA3O used as moisture analyzer
Octagon 2000 used as particle size distribution analyzer (sieve shaker).
Gas adsorption porosimeter (Coulter A31 00)
B. Methods
J. Methods of Tablet Manufacture
In this research project two different devices were prepared:
i. Flat tablet shaped cores were prepared by pouring 400 mg of the
drug/excipient blend, Metoprolol Tartarate into a steel die (1 cm diameter)
and compressed with flat punches at 69.0 MegaPascal, MPa, (10000 lb) for
30 sec. by using a Carver Laboratory press (model C, F. Carver Inc., NJ)
then 200 mg of ethyl cellulose was poured on both sides of the core (top and
bottom) leaving the edge of the core uncoated which represent the window
by which the core can contact the surrounded medium.
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Upper coat (ethyl cellulose)
Flat cote (dtug/excipient)
Lower coat (ethyl cellulose)
Figure 15: flat tablet shaped core
ii. Siconvex cores with central hole were prepared by pouring 400 mg cf the
drug/excipients blend into a steel die (1cm diameter), and compressed with
biconvex punches having an angle 200 with a central rod (1.2mm diameter)
for the formation cf the hole in the middle. This central hole is required for the
creation cf a bridge between the lower and upper coat, to avoid the
separation problems during the dissolution process. The cotes were then
coated as described previously by first pouring 200 mg cf ethyl cellulose in
the die followed by the insertion of the core then 200 mg cf ethyl cellulose
then the upper punch and finally compressed to 69.0 MPa (10000 lb).
Coat (Ethyl cellulose)
Biconvex core with
-
central hole
Figure 16: Radially releasïng biconvex device (RRBD)
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b achieve a controlled release delivery system, we need to have:
a. Coating membrane totally impermeable to water, therefore drugs
can only be released through the uncoated edge of the cote.
b. The core and coat should have good interlocking and be well
adherent, to avoid either infiltration of medium in between the coat
and the cote or separation problems during the dissolution
process, in order to maintain uniform and controlled release of the
drug through the dissolution process.
c. The coating should be in intact until the end of the dissolution
process.
d. An appropriate formula containing drug and appropriate excipients
Figure 17: Cross sectional view of the proposed device
Compressed
Coated Core
Rcleasing Windo
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2. Analytical methods
a) Permeability test
For this proposed device it is critical to evaluate the permeability of the
membrane to ensure that the drug release occurs through the uncoated
perîphery. Therefore, in order to investigate the permeability of the
membrane, the following materials were tested: chitosan, methyl cellulose,
ethyl cellulose and eudragit.
The permeability of ethyl cellulose was tested by using a diffusion celi.
Compartment A was filled with a saturated solution of Aminophylline,
Compartment B contained a buffer solution and a disc of compressed
ethyl cellulose was put between them. The diffusion celi is then placed in
a water bath, compartment A s continuously agitated by using magnetic
stirrer to insure a minimal diffusion layer and homogenous drug solution.
The release kinetics was evaluated by using a U.V. Spectrophotometer.
No significant levels of Aminophylline over a period of 24 hours were
detected indicating that the ethyl cellulose compressed disk is totally
impermeable. (17, 54)
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Table 1, summarizes the results obtained from the diffusion studies
using the coafing materials used for the biconvex core device:
Material Dissolution Period Results
1. Chitosan Less than 10 min Broke
2. Methyl cellulose Less than 10 min Broke
3. Ethyl cellulose Over 18 hours Intact
4. Eudragit RS P0 Over 18 hours Intact
Table 1: Evaluation of the permeability of compressed insoluble polymers
b) Powder characterization
(1) Density
The density was evaluated using the Autotap Quantachrome. A
sample weighing 120g was poured into graduated cylinder, then the ratio
of the powder weight to the volume of the powder (bulk density) was
noted, then tapped 10 times to determine V10 and tapping continued to
determine V500 (tapped 500 time), the volume at which there is no any
change in the density value (true density), as shown in Table 2.
(2) Moisture content
A sample weighing 1.5g (Lactose, Ethyl cellulose, magnesium
stearate, Aminophylline and Metoprolol Tartarate) was spread into the
dish of the moisture analyzer (Sartorius MA3O) under flxed conditions
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(temperature 105°C for 7 min.) then every sample was weighed again to
calculate the difference in the weight which represents the moisture
content. The resuits are shown in the Table 2
Metopro loi Aminophyl- Lactose Ethocel
une (spray dried)
Bulk density rnIV0 g/rnL 0.61 0.53
Tapped density rnlVfinal ghTlL 0.73 0.65
Tapping aptitude mL 13 13
V10-V500 for 1 00g
Compressibility Index % 16.9 18.7
(VOVtinal)/VO* 100
Moisture Content ¾ 0.93 19.07 6.75 8.11
Table 2: Study the densïty, compressibïlity index and moisture content
(3) Powder flow properties
A sample weighïng 110 g (spray dried lactose and ethyl cellulose) was
poured into a funnel with 10 mm and 15 mm outiet orifice diameter. The
time required for 100 g weight of the sample to pass through the orifice of
the funnel represents the flowability of the sample as shown in Table 3.
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Outiet orifice diameter Outiet orifice diameter
Material (l5mrn) (lOmrn)
Mean(S/100) $t. Deviation Mean (S/100) St. Deviation
(S/100) (S/100)
Metoprolol tartarate * * * *
Arninophylline * * * *
Lactose (spray 5.3 0.3 18.6 0.1
dried).
Ethyl cellulose 8.0 0.2 45.4 11.2
* No flow
Table 3: Study the flow property of the used ingredients
Metoprolol, Aminophylline and Magnesium Stearate have poor flow
characteristics because they have small particles sïze, in which the
cohesive forces become stronger than the gravitational force, thereby
affecting the flow through the orifice. This, of course, is a function of the
size of the orifice, and flow might be possible in a larger orifice (which may
flot be relevant).
From Table 3, it is obviously that lactose (spray dried) and ethyl
cellulose have very good flow properties. But in the case of Metoprolol
Tartarate, Aminophylline and Magnesium Stearate they have very poor
flow properties. Since the compressibility index can be a good guide to the
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powder flowability, from Table 2 we see that the compressibility value of
lactose (spray dried) and ethyl cellulose was Iow meaning that both of
them have a good flow property.
(4) Particle Size Analysis
(a) Metoprolol tartarate
As shown in Figure 18 the geometric distribution of particles size of
Metoprolol Tartarate reveals a positive skewed distribution, about 45% of
particles are less than 75pm. in general, fine particles with very high
surface to mass ratios are more cohesive than coarser particles which are
influenced more by gravitational forces. Particles greater than 250pm are
usually relatively free flowing, but as the size fails below lOOpm, powdets
become cohesive and flow problems are likely to occur. Powders having
a particle size less than lOpm are usually extremely cohesive and resist
flow under gravity except possibly as large agglomerates. Since the flow
property is function of particle size, shape and density, the combination of
a high level of fines with rod shaped particles of Metoprolol results in poor
flow properties (see Figure 19).
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Figure 18: Particle size distributîon of Metoprolol Tartarate
Figure 19: Microscopic picture of Metoprolol Tartarate particles
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(b) Aminophylline
As seen in Figure 20, the geometric distribution of Aminophylline
indicates that there are 70% of the particles in the powder having a size
Iess than 75 pm which means that the particle size distribution is skewed
toward fine particles which affect the flow property. Figure 21 as weII
illustrated that the particles size is fine and as a resuit of that
Aminophylline has very poor flow properties
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Figure 20: Particle size distribution of Aminophylline
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Figure 21: Microscopic picture of Aminophylline particles
(c) Lactose (spray dried)
As shown in Figure 22, the particles size distribution of Lactose
reveals that there are less than 20% of the particles having size less than
75pm, and about 80% of the particles size is between 75 to 250pm. As
result of that spray dried lactose has excellent flow properties. In addition
to the compressibility index value of lactose is low which consider as a
good proof for the powder flow ability.
n
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Figure 22: Particle size distribution of Spray Dried Lactose
(U) Ethyl cellulose (Ethocel)
As seen in Figure 23, the geometric distribution of ethocel reveals
that about 18% of the total particles size are less than 45im, and 10%
from 45-75pm, and about 65% of total particles having size from 75 to
500 pm.
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Figure 23: Particle size distribution of Ethyl cellulose
The powder column is a mixed system consisting of a solid particulate
material and air. Air can be present between particles (interparticulate
void) and inside particles (intraparticulate voids). The physical nature of a
powder column is different from that of a solid body, because powder can
fiow and have rheologica properties typical of liquids. On the other hand,
permanent deformation (plasticity), and brittie fracturing of particles,
typical phenomena for solid bodies occur in powders. Therefore, the
behavior of powder in pharmaceutical processes, e.g., during
compression, is often very complicated. In die compaction of powders,
materials are subjected to mechanical forces which Iead to reduce the
volume of powder column. A volume is reduced by decreases in the inter-
Distribution granulométrique
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c) Tablet Porosity
67
and intra particulate pore space. The process of volume reduction is
generally divided into different stages: die fillîng, rearrangement of
particles, deformation by elastic changes, permanent deformation by
plastic flow, or particle failure by brittie fracturing. The measuring of
porosity changes as a function of the compression pressure is a method
wide(y used in describing the compaction processes of powders. (55, 56)
Porosity is a function of the voids in a powder column, and in general
ail pore space s considered, including both inter- and intraparticulate
voids. For porosity measurements, the dimensions and weight of a powder
column (i.e., apparent density) and the particle density (referred to often
as true density) of the solid material should be known. The porosity, E, can
be expressed by the equation:
E ‘1—pA/pT (Equation 36)
d) Dissolution and drug releases studies
The dissolution and drug release studies were achieved using a
Hewlett Packard spectrophotometer (Model HP 8452a diode array) and
Distek dissolution apparatus (Model 2100, NJ) in accordance with the
USP XXII paddle method. Tablets were introduced in dissolution vessels
containing 900 ml of an isotonic phosphate buffer PH 7.4 and subjected to
50 rpm of stirring speed. Amount of drug released was determined
6$
spectrophotometrically at 244nm for aminophylline and 296nm for
metoprolol.
III. Resuits and discussion:
A. Core Coat Development
At the beginning of the core coat design process, the core of the
proposed device was made by using a biconcave punch set with 200 angle
by pouring a specific amount of the blend into a die and compressing at
69.0 MPs (10.000 lb). After that the punches were pulled out and then a
specific amount of coating powder impermeable membrane was added at
the top and the bottom of the compressed biconcave core, and then flat
punches were used to compress the whole tablet (i.e., biconvex core in the
middle and the two layer of the an impermeable membrane) under 69.0
MPs (10.000(b) for 30 second. Within the same procedure and under the
same conditions, another tablet was prepared but in this case the core has
a central hole. Both of the different devices were put into a beakers filled
with 900 ml of buffer solution.
During the first hours of analysis of the release of Aminophylline from
those different devices the core swelled and the aqueous solution starts to
penetrate between the biconvex core and the coating layer. Furihermore
the drug release was much higher than the device (with central hole in the
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core) and after that the two impermeabie coats started to be separated from
the core as shown the Figure 24 While in case of the core with a central
hole the release was constant and the structure of the tablet stayed intact
tilI the end of the dissolution (i.e., until ail the amount of the drug in the cote
was released)
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Figure 24: Study the release of Aminophylline from device with hole in the
coat vs. press-coated device without central hole.
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B. Drug release studies
1. Metoprolol studies
The solubility of the model drug is a very important parameter in the
evaluation of the efficiency of the proposed device. The control of the
release of highly soluble drugs in water is much more difficuit than those of
low solublities. The proposed device was investigated using MT as model
drug. MT belongs to beta1-selective adrenoceptor antagonist with wide
therapeutic usage, especially for hypertension and ischemic heart disease.
It has a relatively short elimination half-life of about 3-4 hours and is
consequently a candidate for an oral controlled-release preparation. Since
MT is highly soluble in water then it is a good model drug to start with. This
study is supported by a previous work conducted in our laboratory (58).
Seven different formulations of MT were evaluated as shown in Table 4.
Formula I II III IV V VI VII
Metoprolol 37.5 37.5 37.5 37.5 37.5 25 50
Mg.Strearate 0.5 1 2 2.5 5 2.5 2.5
Lactose 62 61.5 60.5 60 57.5 72.5 47.5
Table 4: Cote composition, Metoprolol,(%w/w)
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a) The effect of magnesium stearate level on Metoprolol release
kinetics.
As shown in Figure 25, the study of the effect of different
concentrations of MS on the percentage released of Metoprolol Tartrate
(MT) from a Radially Releasing Biconvex Device (RRBD) having a
releasing height of 1 .2mm, where the model drug is released to the
surrounding media, Each device having the same concentration of MT and
different levels of MS and filled up with spray dried lactose as diluent,
(Formula I, III, and V as shown in Table 4). The results show that MS has
a significant effect on the percentage MI released and particularly on the
releasing rate of the drug. By increasing the level of MS, the rate of
release decreased.
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Figure 25: The effect of magnesium stearate loading on Metoprolol
tartarate release (Formula I, III, and V)
As the concentration of the MS increases the release rate decreases
and the release kinetic approaches zero order, (i.e. release curve is more
linear). As seen in Figure 25, in case of 0.5% level of MS in the formula
the percentage released of MT was very high over a short time, therefore,
the release profile showed a very high burst followed by first order release
kinetics. Significant reduction in drug release occurs by increasing the MS
0 2 4 6 8 10 12 14 16 18
Time(h)
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level from 2 to 5% as a result of the increased hydrophobicity induced by
MS. So when the level of MS increases the intrinsic dissolution cf the
blend (core) decreased. This study demonstrated that the ratio of the
constituents of the formula (active to inactive ingredients ratio) has a very
significant effect on the release kinetic in the formulation of this device.
b) The effect of drug loading on release kinetics
The results of the dissolution studies from the proposed device having
different drug loading levels with the same level cf magnesium stearate in
each device, prepared under the same conditions are shown in Figure 26.
The release kinetic profiles for formula VI and IV (25% and 37.5%
drug loading) are significantly different. Formula IV first order while VI near
to zero order. In the case cf formula VII (50% drug loading), where the
drug loading was doubled, the drug release rate was highet and deviated
significantly from zero-order. Since the solubility cf Metoprolol is three to
four times higher than lactose, moreover the ratio cf the highly soluble
portion to 10w soluble portion is high in formula VI resulting to that slower
dissolving core. But in case cf formula Vll(50% loading) it is obvious that
the ratio of highly soluble ingredient to 10w soluble is much higher than
formula VI and IV, leading to the higher release rate for formula VII than
for the release rate for formula VI and IV.
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Figure 26: The eflect of drug loading of Metoprolol on the kinetic release
(formula IV, VI, and VII).
c) The effect of height at the edge (Releasing window) on the drug
release
In this study the objective was to evaluate the effect of the surface
area at the releasing surface on the percentage of drug released as a
function of time. The devices were made up under the same conditions
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and trom the same blend as formula IV but with different heights at the
edge of the tablet core, 0.5, 1.0, 1.5, 2.0, and 3.0 mm.
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Figure 27: The effect of height at the edge (releasing window) on the drug
release (formula IV)
As shown in Figure 27, in ail cases, the release rates increased as the
height at the edge increased f rom 0.5 to 3mm. it is obviousIy that there is
a significant effect of the core peripheral height on the release kinetics.
The increase in area exposed to surrounded media accelerated the
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—O— Time(h) vs lmm height
—e--— Time(h) vs 1 .5mm height
—y-— Time(h) vs 2mm height
—e-— Time(h) vs 3 mm height
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dissolution process, therefore decreasing the time for 100% release. From
Figure 27, in the case of 3 mm height, more than 85% of the drug is
released within 4 hours while in the case of 1 mm height it took more than
10 hrs to reach 85% pfdrug released.
U) The release of MT of formula IV from devices: Flat and Biconvex
cotes.
Figure 28, demonstrates the percentage released of MT from
biconvex vs. flat core devices. Both cores are made from the same blend
(formula IV), pressed under the same compression force 69.0 MPs,
(10.000lb), the same dwell time and had the same releasing surface area.
As seen in Figure 28, it is obvious that the release of the drug model,
MT, from the proposed device is more constant and doser to zero order
than in the case of the flat cote device. Therefore, the drug release profile
can be controlled over a more extended period cf time with the proposed
device as opposed to the continuously diminishing rate achieved from flat
device. Figure 29, illustrates the release rate of MT from the two different
devices, and it is clear that the release rate from the proposed device is
more constant over a more prolonged period cf time than in case of flat
cote device which is characterized by a very high burst followed by a
rapidly decreasing rate until exhaustion.
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Figure 28: Study the effect of bïconvex vs. flat core device on the release of
Metoprolol tartarate (formula IV)
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Figure 29: The release rate of Metoprolol from flat core device vs.
biconvex cote device
e) Study the influence of agitation rate on the kinetics profile
The proposed device containing formulation IV was tested under three
different speed of agitation namely 50,100 and 150 rpm and the results
are presented in Figure 30.lt is clearly that the effect of increasing the
speed of agitation on the release rate, from the proposed device, is very
obvious. The high increase in release rate, with increasing agitation
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speed, from 50 to 100 then to 150 observed for formulation IV can be
attributed to decreasing diffusion layer at the dissolution front leading to
decrease the path length of diffusion as expected for dissolution system.
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Figure 30: Study the effect of agitation speed on the kinetic profile of
Metoprolol tartarate (formula IV).
$0
2. AminophylIine studies
Aminophylline is a very soluble drug in water. In this research
Aminophylline was selected as the second model drug in order ta show the
suitability of the proposed device and its reproducibility to contrai the
release of a drug.
Formula VIII IX X XI
Aminophylline 33 33 33 33
Ethyl cellulose 40 30 20 15
Lactose(USP) 27 37 47 52
Table 5: Cote composition, Aminophyttine, (%wlw)
a) The effect of compression force on Aminophyilïne kinetic profile
The objective of this study was ta investigate and validate the
influence of the applied mechanical force on the kinetic profile of
Aminophylline used as a model drug In order ta determine the minimal
compression force above which the porosity value does not further
decrease (i.e., at which the increase in mechanical force is meaningiess).
Three devices were made from the same biend (formula VIII) and pressed
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—e— Time (h) vs 34.5 MPa
—O-— Time (h) vs 69.0 MPa
—-v-— Time (h) vs 103.4 MPa
Figure 31: Study the effect of compression force on Aminophylline kinetîc
profile (Formula VIII)
under three different compression forces 34.5, 69.0, 103.4 MPa (5.000 lb,
10.000 lb, and 15.000Ib) for the same dwell time (30 sec.). The tablets
were put in beaker filled with 900 ml of phosphate buffer (7.4pH); the
kinetic profile was investigated by spectrophotometry at 244nm.
As seen in Figure 31, it is clear that the release of AM f rom the three
devices was similar which demonstrates that there is no significant
difference in porosity values between the three devices.
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To demonstrate the 10w porosity a Coulter SA 3100 was used to
measure the porosity and pore size distribution of each tablet pressed
under different compression force 34.5, 69.0, 103.4 MPa (5.0001b,
1O.000Ib, and 15.000Ib). As seen in Table 6, and by comparing the
compression force used with the total pore volume for every sample
(tablet). The resuits revealed that there is no significant effect of
compression force on the total pore volume above 34.5 MPa (5000 lbs)
(i.e. total pore volume of tabtet compressed at 34.5 MPa (5000 lbs) was
0.0024 mLIg, at 69.OMPa, 10000 lbs was 0.0050 and at 103.4 MPa
(15000 Ibs) was 0.0051 mg/MI), therefore the compression force does not
affect on the porosity value. But in case of pore size distribution and as
shown in figure 32 the compression force has an obvious influence on the
pore size distribution of each tablet. The resuits demonstrated that by
increasing the compression force the pore size decreased. As seen in the
Figure 32 in the case of compression force of 34.5 MPa (50001b) the pore
size distribution is wide. And by increasing the compression force to 69.0
MPa (10.000 lb) the pore diameter range decreased to less than 6 nm.
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Pore diameter(nm) % of 34.4 MPa ¾ of 69.0 MPa ¾ of 103.4 MPa
under6 10.9 99.99 99.99
6to8 10.46 0 0
8tolO 9.01 0 0
lOtol2 8.44 0 0
12to16 9.96 0 0
16to20 6.61 0 0
20to80 36.92 0 0
over8û 7.7 0 0
Table 6: Pore size distribution of different disks compressed under
different forces
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Figure 32: The effect of compression force on the pore size distrïbution
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b) The effect of ethyl cellulose on Aminophylline release profile
This study evaluated the influence of ethyl cellulose as an excipient on
the release of AM from the proposed device. Four devices were made
according to the formulations (VIII, IX, X and Xl), which contain 40%, 30%,
20% and 15% respectively, as shown in Table 5. The four devices were
made under the same condition, and the release profile was monitored by
using a spectrophotometer for 18 hours.
Figure 33 demonstrates the effect of increasing the ethyl cellulose
level in each formula. By increasing the level of ethyl cellulose from 15 to
20% there is very significant effect on the release kinetic. By furiher
increasing the level of ethyl cellulose from 20% to 30% does not have as
significant an effect on the release kinetic, because at the 15% ethyl
cellulose level in formula Xl the core dissolves gradually allowing drug to
diffuse through the media. In formula X (20% ethocel) the ethyl cellulose
forms a gel that remains within the tablet which decreases significantly
drug diffusion from the core. By increasing the level 0f ethyl cellulose to
levels higher than 20% does not have as significant an effect because
there is probably flot a very significant change in the physical state of the
gel. Therefore, there is a significant effect on the release kinetic by
increasing the amount of ethyl cellulose to a critical level above which
there is only a small effect on the release kinetic, Furthermore with
increasing ethyl cellulose levels the release rate of Aminophylline is
reduced, and the kinetic profile of the drug approaches zero-order.
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Figure 33: The effect of ethyl cellulose level on Aminophylline release
(formula VIII, IX, X, and XI)
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—y-— lime (h) vs 40% ethyl cellulose level
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c) The study of Aminophylline from biconvex and flat core devices
In this experiment the cotes cf both devices were made from the same
blend of formula X as shown in Table 5, in equal amounts as well, using
the flat punches for one set and using biconcave punches with 200 angle
and hole in the middle for the other set. Both sets of devïces were
compressed under the same compression force 69.0 MPa (10.000lb) for
30 sec. Figure34 obviously shows the advantage of using a biconvex over
a flat device in providing a well controlled drug release rate over an
extended period of time. In this Figure it is clearly that the proposed
devices achieved a very close to zero-order kinetic behavior comparing to
the flat devices. Figure 35, shows the rate of release of the two different
devices and it is obvious that the release rate from the proposed device is
much doser to zero order that in the flat core device. From the results it is
noticeably that the advantage of using biconvex devices to an extend
period of time is very clear over the flat devices.
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Figure 34: Study of Aminophylline release from biconvex vs. flat core
device (Formula X)
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Figure 35: The rate of Aminophylline released from flat core vs. bîconvex
cote devices
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IV. Conclusion
The resuits presented in this research work demonstrated the flexibility of
the developed system, in adjusting drug dissolution rate through the judicious
selection of excipients. The influence of adjusting the drug loading level, and the
level of lactose (filler) at constant and increasing levels of Magnesium Stearate
revealed that the ratio of these ingredients is very significant in controlting the
release of drugs. When lactose was used with highly soluble drugs like
Metoprolol Tartarate, the formula needed high level of Magnesium Stearate
(hydrophobic) to significantly lower the intrinsic dissolution of the blend and
consequently the dissolution rate. In the case of the second model drug
(Aminophylline), the effect of changing the level of Lactose and Ethyl cellulose at
constant model drug level, revealed that the ratio of the ingredient in the
formulation (revealed by its intrinsic dissolution) is very significant in the control
of the release kinetics. The study of the effect of the releasing surface area of the
RRB device was studied by varying the height at the releasing surface area. The
results show that as the height of the releasing surface decreases the kinetics
tends to approach zero order. Studies of the effect of the geometry of the
proposed device compared to a flat core device suggested that the release
kinetic profile is near to zero-order in the case of the proposed device while for
the flat core device the release kinetics is typical first order because Radially
Releasing Biconvex Device (RRBD) compensates for the increase in diffusional
distance by increasing the surface of the dissolutional front resulting in more drug
solubilized per unit time.
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This research studied another important aspect, associated with the
manufacturing process of the proposed device which is the compressional force.
The core should be adequately hard to reduce the porosity, therefore avoiding
the infiltration of dissolution medium. Moreover the core should have a central
hole to prevent the separation problems and keep the whole device intact until
the end cf the dissolution process.
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V. Appendix
1
Appendix 1: Pharma test PTG-1 used as a fIow meter
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Append ix 2: Auto tap
93
Appendix 3: Particle size analysis machine fOCTAGON2000)
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Poids des tamis % différentiels % passant cumulés
TAMIS Vide Plein Poudre (j.im) % (tm) %
Mesh (g) (g) (g) <45 11.70 0 0.00
20 348.91 349.39 0.48 45-75 33.75 45 11.70
35 322.91 324.13 1.16 75-150 24.60 75 45.45
60 297.18 303.80 6.62 150-250 12.05 150 70.05
100 286.56 292.12 5.56 250-500 14.35 250 82.10
200 315.50 326.85 11.35 500-850 2.51 500 96.45
325 320.75 336.32 15.57 >850 1.04 850 98.96
réceptacle 255.92 261.32 5.40 Total 100.00 1680 100.00
Total: 46.14
Êchant. 46.14
(g): ¾ Récup: 100.00 Moyenne iim 154
Appendix 4: Data of particle size analysis of Metoprolol Tartarate
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Appendix 5: Cumulated distribution of the particles of Metoprolol Tartarate
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Poids des tamis % différentiels % passant cumulés
Tamis Vide plein Poudre (jim) % (tm) %
Mesh (g) (g) (g) <45 36.34 0 0.00
20 349.04 348.97 -0.07 45-75 32.76 45 36.34
35 322.90 322.84 -0.06 75-150 22.05 75 69.10
60 297.23 298.21 0.98 150-250 5.18 150 91.15
100 286.84 288.04 1.20 250-500 4.23 250 96.33
200 315.56 320.67 5.11 500-850 -0.26 500 100.56
325 320.69 328.28 7.59 >850 -0.30 850 100.30
réceptacle 255.90 264.32 8.42 Total 100.00 1680 100.00
Total: 23.17
Échant. 24.36 % Récup: 95.11 Moyenne tm 75
(g):
Appendix 6: Data of particle size analysis of Amïnophyllïne
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Appendix 7: Cumulated distribution of the particles of Aminophylline
—.-—Aminophyllin batch #
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Poids des tamis % différentiels % passant cumulés
Tamis Vide plein poudre (tm) % (tm) %
Mesh (g) (g) (g) <45 10.04 0 0.00
20 349.27 349.2$ 0.01 45-75 8.4$ 45 10.04
35 322.96 323.13 0.17 75-150 38.16 75 18.53
60 296.97 298.94 1.97 150-250 41.00 150 56.69
100 286.54 324.67 38.13 250-500 2.12 250 97.69
200 315.55 351.04 35.49 500-$50 0.18 500 99.81
325 320.51 328.40 7.89 >850 0.01 $50 99.99
Réceptacle 255.81 265.15 9.34 Total 100.00 1680 100.00
Total: 93.00
Echant.(g) 92.79 % Récup: 100.23 Moyenne tm 142
Appendix 8: Data of particle sïze distribution of Lactose
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Appendix 9: Cumulated distribution of the particles of Lactose
Distribution cumulée
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Lactose batch #
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Poids des tamis % différentiels % passant cumulés
Tamis Vide Plein Poudre (jim) % Q.trn) %
Mesh (g) (g) (g) <45 18.85 0 0.00
20 349.18 349.37 0.19 45-75 10.28 45 18.85
35 322.97 327.82 4.85 75-150 19.08 75 29.13
60 297.32 317.41 20.09 150-250 19.57 150 48.21
100 286.66 301.92 15.26 250-500 25.76 250 67.78
200 315.70 330.58 14.88 500-$50 6.22 500 93.54
325 320.82 328.84 8.02 >850 0.24 $50 99.76
réceptacle 255.96 270.66 14.70 Total 100.00 1680 100.00
Total: 77.99
Echant.(g) 78.79 ¾ Récup: 98.98 Moyenne jim 212
n
Appendix 10: Data of particle size analysis of Ethyl cellulose (ethocel)
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Appendix 11: Cumulated distribution of the particles of Ethyl cellulose
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